EBSEmergent BioSolutions Inc.

$433M

Q4 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$194M+27.8% YoY

Gross Profit

$110M56.5% margin

Operating Income

$53M27.4% margin

Net Income

$34M17.5% margin

EPS (Diluted)

$0.67

QoQ Revenue Growth

+29.7%

Cash Flow

Operating Cash Flow

$79M

Free Cash Flow

$67M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$158M

Stockholders' Equity

$912M

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$194M	$152M	+27.8%
Gross Profit	$110M	$86M	+26.9%
Operating Income	$53M	$51M	+4.2%
Net Income	$34M	$37M	-9.2%

EBS Q4 2017 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena